扶正化瘀胶囊联合阿德福韦酯治疗慢性乙型肝炎肝纤维化的系统评价

发布时间：2018-05-12 10:12

  本文选题：扶正化瘀胶囊 + 阿德福韦酯　； 参考：《中草药》2017年18期

【摘要】：系统评价扶正化瘀胶囊联合阿德福韦酯治疗慢性乙型肝炎肝纤维化的疗效和安全性。计算机检索万方、中国知网、维普、中国生物医学、Pub Med、Cochrane、Embase等数据库,搜集扶正化瘀胶囊联合阿德福韦酯治疗慢性乙型肝炎肝纤维化的随机对照试验(RCT),检索时间从建库至2017年3月。由2位研究者独立筛选文献、提取资料、评价文献质量。采用Rev Man 5.3软件对所提取的数据资料进行Meta分析。共纳入13项研究,1 400例研究对象。Meta分析结果显示,与单用阿德福韦酯相比,扶正化瘀胶囊联合阿德福韦酯不仅可以降低慢性乙型肝炎肝纤维化患者血清肝纤维化指标:HA[MD=-99.66,CI=-129.94~-69.37,P0.000 01]、LN[MD=-40.99,CI=-58.56~-23.41,P0.000 01]、PCIII[MD=-76.40,CI=-108.15~-44.66,P0.000 01]、IV-C[MD=-55.24,CI=-79.19~-31.29,P0.000 01];还能明显改善肝功能指标:ALT[MD=-21.05,CI=-22.58~-19.52,P0.000 01]、AST[MD=-16.74,CI=-25.14~-8.33,P0.000 1]、TBIL[MD=-10.38,CI=-14.17~-6.59,P0.000 01]、ALB[MD=4.35,CI=-3.48~5.23,P0.000 01],改善B超影像学结果,且无明显不良反应。扶正化瘀胶囊联合阿德福韦酯能显著改善肝功能,降低肝纤维化指标,且不良反应少,但尚需通过更多大样本、高质量的临床试验进一步验证其疗效。
[Abstract]:To evaluate the efficacy and safety of Fuzheng Huayu capsule combined with adefovir in the treatment of chronic hepatitis B liver fibrosis. To search the databases of Wanfang, Zhiwang, Weipu, Pub Meden Cochraneto Embase and so on, a randomized controlled trial of Fuzheng Huayu capsule combined with adefovir in the treatment of chronic hepatitis B liver fibrosis was conducted. The retrieval time was from the establishment of the database to March 2017. Two researchers independently sifted the literature, extracted the data and evaluated the quality of the literature. The extracted data were analyzed by Meta using Rev Man 5.3 software. A meta-analysis of 1 400 subjects included in 13 studies showed that compared with adefovir alone, 鎵舵�ｅ寲鐦�鑳跺泭鑱斿悎闃垮痉绂忛煢閰�涓嶄粎鍙�浠ラ檷浣庢參鎬т箼鍨嬭倽鐐庤倽绾ょ淮鍖栨偅鑰呰��娓呰倽绾ょ淮鍖栨寚鏍，

本文编号：1878192